Kiniksa Pharmaceuticals International, plc $KNSA Stock Position Decreased by Goldman Sachs Group Inc.

Key Points

• Goldman Sachs Group Inc. has reduced its stake in Kiniksa Pharmaceuticals by 26%, selling 54,859 shares, and now holds about 0.21% of the company, valued at $3.47 million.
• Kiniksa Pharmaceuticals has seen increased interest from other investors, with institutions owning 53.95% of its shares, and several firms upgrading their ratings with target prices ranging from $36 to $54 per share.
• In insider trading, significant sales were made by executives, including CAO Michael R. Megna who sold 17,000 shares, contributing to over 561,000 shares sold by insiders in the last ninety days.

Goldman Sachs Group Inc. decreased its stake in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) by 26.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 156,328 shares of the company's stock after selling 54,859 shares during the period. Goldman Sachs Group Inc. owned approximately 0.21% of Kiniksa Pharmaceuticals International worth $3,472,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in KNSA. GAMMA Investing LLC raised its stake in shares of Kiniksa Pharmaceuticals International by 84.8% during the 1st quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock worth $27,000 after buying an additional 568 shares during the last quarter. US Bancorp DE acquired a new position in shares of Kiniksa Pharmaceuticals International during the 1st quarter worth $33,000. Asset Management One Co. Ltd. acquired a new position in shares of Kiniksa Pharmaceuticals International during the 1st quarter worth $41,000. Wealthquest Corp acquired a new position in Kiniksa Pharmaceuticals International in the 1st quarter valued at about $42,000. Finally, Lazard Asset Management LLC acquired a new position in Kiniksa Pharmaceuticals International in the 4th quarter valued at about $61,000. Institutional investors and hedge funds own 53.95% of the company's stock.

Insider Transactions at Kiniksa Pharmaceuticals International

In related news, insider Ross Moat sold 3,523 shares of the company's stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $35.31, for a total transaction of $124,397.13. Following the sale, the insider directly owned 9,415 shares of the company's stock, valued at approximately $332,443.65. This represents a 27.23% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Thomas Malley sold 78,233 shares of the company's stock in a transaction that occurred on Thursday, August 14th. The shares were sold at an average price of $33.09, for a total value of $2,588,729.97. Following the sale, the director directly owned 12,546 shares in the company, valued at approximately $415,147.14. This represents a 86.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 561,371 shares of company stock valued at $18,825,009. 53.48% of the stock is currently owned by insiders.

Kiniksa Pharmaceuticals International Stock Down 1.4%

Shares of Kiniksa Pharmaceuticals International stock traded down $0.50 on Friday, hitting $35.42. 489,203 shares of the company's stock traded hands, compared to its average volume of 386,927. The stock has a market cap of $2.62 billion, a P/E ratio of 885.72 and a beta of 0.20. The firm's 50-day moving average is $32.62 and its 200 day moving average is $27.61. Kiniksa Pharmaceuticals International, plc has a 52-week low of $17.82 and a 52-week high of $37.34.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last released its earnings results on Tuesday, July 29th. The company reported $0.23 EPS for the quarter, beating the consensus estimate of $0.18 by $0.05. The company had revenue of $156.80 million during the quarter, compared to analysts' expectations of $145.21 million. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. Equities research analysts forecast that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. Wells Fargo & Company boosted their target price on shares of Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the company an "overweight" rating in a research note on Wednesday, July 9th. Wall Street Zen raised shares of Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a research note on Sunday, September 7th. Wedbush reiterated an "outperform" rating and set a $36.00 target price on shares of Kiniksa Pharmaceuticals International in a report on Monday, July 21st. Finally, Jefferies Financial Group boosted their target price on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a "buy" rating in a report on Tuesday, July 29th. Six investment analysts have rated the stock with a Buy rating, According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $41.17.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.